Final Results from a Study of Adjuvant Therapy in Stage III Melanoma

An overall survival benefit is still elusive after nearly 10 years of follow-up in the randomized, placebo-controlled COMBI-AD trial comparing dabrafenib and trametinib versus placebo.

For patients with stage III melanoma, the goal is cure, but the risk of relapse is high. Randomized, placebo-controlled studies such as COMBI-AD, initially reported in 2017 (N Engl J Med 2017; 377:1813), set the standard that has since been followed: complete surgical resection followed by adjuvant therapy to reduce the risk of recurrent disease by eliminating micrometastases. In the same decade, several studies clearly demonstrated a benefit for adjuvant treatment of resected stage III melanoma, which led to a bounty of FDA-approved options, including checkpoint-blocking antibodies (ipilimumab, nivolumab, pembrolizumab) and the targeted inhibitor combination of dabrafenib and trametinib.

Now, researchers report final results from the indust…

Reviewing Author

Margaret Callahan, MD, PhD

Disclosures

Consultant/Advisory BoardBristol Myers Squibb, Immunocore, AstraZeneca/MedImmune

EquityMerus

Grant/Research SupportNIH, V Foundation

Margaret Callahan, MD, PhD

Disclosures

Consultant/Advisory BoardBristol Myers Squibb, Immunocore, AstraZeneca/MedImmune

EquityMerus

Grant/Research SupportNIH, V Foundation

Final Results from a Study of Adjuvant Therapy in Stage III Melanoma

Topics

Reviewing Author